These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 15860590)

  • 1. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
    Haynes BF; Fleming J; St Clair EW; Katinger H; Stiegler G; Kunert R; Robinson J; Scearce RM; Plonk K; Staats HF; Ortel TL; Liao HX; Alam SM
    Science; 2005 Jun; 308(5730):1906-8. PubMed ID: 15860590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
    J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.
    Scherer EM; Zwick MB; Teyton L; Burton DR
    AIDS; 2007 Oct; 21(16):2131-9. PubMed ID: 18090039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
    Zhang MY; Vu BK; Choudhary A; Lu H; Humbert M; Ong H; Alam M; Ruprecht RM; Quinnan G; Jiang S; Montefiori DC; Mascola JR; Broder CC; Haynes BF; Dimitrov DS
    J Virol; 2008 Jul; 82(14):6869-79. PubMed ID: 18480433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.
    Finton KA; Larimore K; Larman HB; Friend D; Correnti C; Rupert PB; Elledge SJ; Greenberg PD; Strong RK
    PLoS Pathog; 2013; 9(9):e1003639. PubMed ID: 24086134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
    Alam SM; Scearce RM; Parks RJ; Plonk K; Plonk SG; Sutherland LL; Gorny MK; Zolla-Pazner S; Vanleeuwen S; Moody MA; Xia SM; Montefiori DC; Tomaras GD; Weinhold KJ; Karim SA; Hicks CB; Liao HX; Robinson J; Shaw GM; Haynes BF
    J Virol; 2008 Jan; 82(1):115-25. PubMed ID: 17942537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
    Shen X; Parks RJ; Montefiori DC; Kirchherr JL; Keele BF; Decker JM; Blattner WA; Gao F; Weinhold KJ; Hicks CB; Greenberg ML; Hahn BH; Shaw GM; Haynes BF; Tomaras GD
    J Virol; 2009 Apr; 83(8):3617-25. PubMed ID: 19193787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J; Wyatt RT
    PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
    Montero M; van Houten NE; Wang X; Scott JK
    Microbiol Mol Biol Rev; 2008 Mar; 72(1):54-84, table of contents. PubMed ID: 18322034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
    Yang G; Holl TM; Liu Y; Li Y; Lu X; Nicely NI; Kepler TB; Alam SM; Liao HX; Cain DW; Spicer L; VandeBerg JL; Haynes BF; Kelsoe G
    J Exp Med; 2013 Feb; 210(2):241-56. PubMed ID: 23359068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PW
    J Virol; 2001 Nov; 75(22):10892-905. PubMed ID: 11602729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
    Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.
    Venditto VJ; Wieczorek L; Molnar S; Teque F; Landucci G; Watson DS; Forthal D; Polonis VR; Levy JA; Szoka FC
    Clin Vaccine Immunol; 2014 Aug; 21(8):1086-93. PubMed ID: 24872518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
    Virology; 2017 May; 505():113-126. PubMed ID: 28237764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
    Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
    J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens.
    Dennison SM; Anasti K; Scearce RM; Sutherland L; Parks R; Xia SM; Liao HX; Gorny MK; Zolla-Pazner S; Haynes BF; Alam SM
    J Virol; 2011 Feb; 85(3):1340-7. PubMed ID: 21106741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.